Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Raw Materials (2022 - 2025)

Historic Raw Materials for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $394000.0.

  • BioXcel Therapeutics' Raw Materials fell 5270.11% to $394000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $394000.0, marking a year-over-year decrease of 5270.11%. This contributed to the annual value of $506000.0 for FY2024, which is 4588.24% down from last year.
  • As of Q3 2025, BioXcel Therapeutics' Raw Materials stood at $394000.0, which was down 5270.11% from $433000.0 recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' Raw Materials peaked at $935000.0 during Q4 2023, and registered a low of $394000.0 during Q3 2025.
  • For the 4-year period, BioXcel Therapeutics' Raw Materials averaged around $674642.9, with its median value being $682000.0 (2022).
  • In the last 5 years, BioXcel Therapeutics' Raw Materials soared by 3709.68% in 2023 and then tumbled by 5270.11% in 2025.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Raw Materials stood at $682000.0 in 2022, then skyrocketed by 37.1% to $935000.0 in 2023, then crashed by 45.88% to $506000.0 in 2024, then fell by 22.13% to $394000.0 in 2025.
  • Its Raw Materials stands at $394000.0 for Q3 2025, versus $433000.0 for Q2 2025 and $464000.0 for Q1 2025.